Close Menu

    Subscribe to Updates

    Get the latest creative news from Healthradar about News,Health and Gadgets.

    Bitte aktiviere JavaScript in deinem Browser, um dieses Formular fertigzustellen.
    Wird geladen
    What's Hot

    Exploring Perplexity.aI: Essential AI Toolkit Insights

    5. Juni 2025

    Over $1 billion in federal funding got slashed for this polluting industry

    5. Juni 2025

    Inside the Bloodbath at the NIH. Sources say that a climate of fear has spread throughout the agency as the Trump administration takes a hatchet to its core functions.

    5. Juni 2025
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram Pinterest Vimeo
    healthradar.nethealthradar.net
    • Home
    • Ai
    • Gadgets
    • Health
    • News
    • Contact Us
    Contact
    healthradar.nethealthradar.net
    Home»Health»Zepbound More Effective Than Wegovy, Clinical Trial Shows
    Health

    Zepbound More Effective Than Wegovy, Clinical Trial Shows

    HealthradarBy Healthradar1. Juni 2025Keine Kommentare5 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Reddit Telegram Email
    Zepbound More Effective Than Wegovy, Clinical Trial Shows
    Share
    Facebook Twitter LinkedIn Pinterest Email


    Eli Lilly Zepbound injectionShare on Pinterest
    Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly. Shelby Knowles/Bloomberg/Getty Images
    • Zepbound outperformed Wegovy for weight loss in a clinical trial sponsored by Eli Lilly.
    • Participants who received tirzepatide, the active ingredient in Zepbound, also had greater reductions in waist size and more significant improvements in metabolic risk factors.
    • Tirzepatide’s dual effects on GLP-1 and GIP may explain its superior performance over semaglutide, the active ingredient in Wegovy.
    • Lack of insurance coverage and high costs remain a barrier to obtaining tirzepatide.

    Eli Lilly’s weight loss drug Zepbound outperformed competitor Novo Nordisk’s Wegovy, according to a clinical trial funded by Lilly.

    The SURMOUNT-5 trial, a Phase 3b open-label clinical trial, examined the safety and efficacy of tirzepatide, the active ingredient in Zepbound.

    When compared with semaglutide (Wegovy), which is selective for one type of receptor versus the two targeted by tirzepatide, Zepbound was found to be more effective.

    Study participants using tirzepatide lost more weight after 72 weeks (average loss of 20.2% compared to 13.7% for semaglutide). This translates to an average of 50.3 pounds for those using tirzepatide and 33.1 pounds for those using semaglutide.

    It was additionally noted that significantly more tirzepatide users achieved at least 15.0% weight loss and a greater reduction in their waist circumference.

    Lilly’s study compared the drugs tirzepatide and semaglutide in adults with obesity but without diabetes.

    Altogether, 751 individuals were randomly assigned to receive the maximum tolerated dose of one of the two medications on a weekly basis. Of these, 750 received at least one dose.

    However, tirzepatide was more likely to help participants achieve major weight-loss milestones.

    Nearly one-third (32%) of participants experienced a 25% or more body weight reduction due to tirzepatide. By comparison, those who received semaglutide experienced a 16% reduction in body weight.

    Side effects were mostly mild to moderate gastrointestinal issues such as nausea and diarrhea, occurring mainly during dose increases.

    Although both medications had similar overall safety profiles, semaglutide users experienced slightly more treatment discontinuations due to gastrointestinal side effects.

    Tirzepatide users reported more injection-site reactions, like redness or irritation, but these were generally not severe.

    Still, some experts, like Austin Shuxiao, MD, a board certified internal medicine physician and founder of Peach IV, who was not involved in the study, advised caution in interpreting the results.

    “It is important to point out that Eli Lilly is both the maker of Zepbound and the sponsor for this study,” he told Healthline.

    “This represents a clear conflict of interest, which is common in these head-to-head studies, and is always good to keep in mind before we take the study at face value,” Shuxiao noted.

    Experts suggest that tirzepatide’s dual mechanism of action, targeting two metabolic receptors, may explain its superior weight-loss results compared to semaglutide’s single-receptor approach.

    Raj Dasgupta, MD, chief medical advisor for Sleepopolis, who was also not a part of the study, explained that it is believed that tirzepatide acts on both GLP-1 (glucagon-like peptide-1) receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors.

    Semaglutide, however, only acts on GLP-1 receptors.

    “That second pathway seems to give Zepbound an extra edge when it comes to appetite control and how the body handles energy and fat,” Dasgupta told Healthline.

    “In real-world terms, that means many patients on Zepbound are losing more weight than those on Wegovy,” he noted.

    Dasgupta described the results of the trial as a “big deal’ for people with obesity.

    “We now have more than one highly effective option, and Zepbound seems to be leading the pack,” he said.

    An important implication, for instance, is that if a person doesn’t respond well or experiences intolerable side effects with one weight loss medication, they have another option to try.

    “That kind of flexibility is important because weight loss isn’t the same journey for everyone,” Dasgupta said.

    “If you’ve plateaued or had a tough time with side effects, it’s worth asking your doctor whether Zepbound might be a better fit,” he advised.

    However, if you’re doing well on Wegovy, there’s no need to switch, he noted.

    Of course, it’s important to keep in mind that no single medication is a magic bullet for weight loss.

    “The best results still come when people combine these treatments with changes in diet, sleep, movement, and stress — things we work on together over time,” Dasgupta said.

    Shuxiao said that while tirzepatide could become a first-line choice for obesity treatment, it’s more expensive and tends to be less covered by insurance.

    “Insurance will dictate patients’ access to medication, not clinical preference,” he said, noting that he has greater difficulty getting tirzepatide approved for his patients, especially if they have suboptimal insurance plans.

    Still, Shuxiao said he feels that anyone who is in the overweight-obesity BMI range should consider GLP-1 medications, provided there are no contraindications.

    “GLP-1 agonists are the most effective weight loss medication in human history, and if they are proven free of long-term side effects, they will remain a staple in modern medicine,” he said.

    The SURMOUNT-5 trial reinforces tirzepatide’s role as a leading treatment option for obesity, offering greater weight loss and metabolic benefits than semaglutide in adults without diabetes.

    With its dual-targeting mechanism acting on both GLP-1 and GIP receptors, tirzepatide appears to provide more robust appetite regulation and fat metabolism.

    While both medications were generally well tolerated, differences in side effect profiles and insurance coverage may guide individual treatment decisions.

    Experts agree that the findings are encouraging, but also stress the importance of a holistic approach to weight management. Medication alone isn’t a cure — sustainable success still hinges on long-term lifestyle changes.

    As more options become available, patients and providers can better tailor treatment to individual needs and preferences.

    However, the financial accessibility of these medications remains a concern. As research continues and coverage improves, tirzepatide may become a cornerstone of obesity care — but only if patients can afford to access it.



    Source link

    Clinical Effective shows Trial Wegovy Zepbound zepbound wegovy weight loss clinical trial
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleBag the Apple Watch Series 10 for only $299 this Memorial Day
    Next Article Illinois House passes bill allowing terminally ill people to end their lives with physician’s help
    ekass777x
    Healthradar
    • Website

    Related Posts

    Health

    Inside the Bloodbath at the NIH. Sources say that a climate of fear has spread throughout the agency as the Trump administration takes a hatchet to its core functions.

    5. Juni 2025
    Health

    3-Year Exercise Program Improves Colon Cancer Survival Rates

    4. Juni 2025
    Health

    watchOS 12: 3 things I expect to see Tim Cook announce at this year’s WWDC

    3. Juni 2025
    Add A Comment
    Leave A Reply Cancel Reply

    Top Posts

    Which Online Poker Game Should You Play?

    31. Mai 20259 Views

    New surgeon general nominee cofounded a16z backed health app with DOGE operative

    1. Juni 20254 Views

    One In Four European Firms Ban Grok AI Chatbot Over Security Concerns

    1. Juni 20252 Views

    Bayer Launches Centafore Imaging Core Lab to Support Imaging for Clinical Trials and Software as a Medical Device Development

    1. Juni 20252 Views
    Stay In Touch
    • Facebook
    • YouTube
    • TikTok
    • WhatsApp
    • Twitter
    • Instagram
    Latest Reviews

    Subscribe to Updates

    Bitte aktiviere JavaScript in deinem Browser, um dieses Formular fertigzustellen.
    Wird geladen
    About Us

    Welcome to HealthRadar.net — your trusted destination for discovering the latest innovations in digital health. We are dedicated to connecting individuals, healthcare professionals, and organizations with cutting-edge tools, applications

    Most Popular

    Which Online Poker Game Should You Play?

    31. Mai 20259 Views

    New surgeon general nominee cofounded a16z backed health app with DOGE operative

    1. Juni 20254 Views
    USEFULL LINK
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    QUICK LINKS
    • Ai
    • Gadgets
    • Health
    • News
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    Copyright© 2025 Healthradar All Rights Reserved.

    Type above and press Enter to search. Press Esc to cancel.